Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ACHV with free AI briefings, catalyst countdowns, and dilution alerts.

ACHV · ACHIEVE LIFE SCIENCES, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$203.5M Cash on Hand
63.8mo Cash Runway
0% Short Interest
$13.75 Analyst Target (12)
Follow ACHV by email Get an email when ACHV reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ACHV, unsubscribe in one click. Privacy

📣 What ACHV Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
TOCOSOL Paclitaxel Breast Neoplasm Phase 3 · NCT00251095 Terminated
Paclitaxel Breast Neoplasm Phase 3 · NCT00251095 Terminated
Custirsen Non-Small Cell Lung Cancer Phase 3 · NCT01630733 Completed
Custirsen Sodium Prostate Cancer Phase 3 · NCT01578655 Completed
Cytisinicline Vaping Cessation Phase 3 · NCT07392125 Not yet recruiting
isotonic, 0.9% sodium chloride Castrate-Resistant Prostate Cancer Phase 3 · NCT01083615 Terminated
Paclitaxel Vitamin E-Based Emulsion (S-8184) Ovarian Cancer Phase 2 · NCT00034151 Completed
Apatorsen (OGX-427) Urologic Neoplasms Phase 2 · NCT01454089 Completed
Experimental Arm: TOCOSOL Paclitaxel Urologic Neoplasms Phase 2 · NCT00034177 Completed
Moxifloxacin Smoking Cessation Phase 1 · NCT05566288 Completed
Tenifatecan (SN2310) Breast Neoplasms Phase 1 · NCT00385177 Completed

Also used in these trials (approved or third-party drugs, not ACHV's own candidates): Cabazitaxel, Prednisone, Dexamethasone, Docetaxel Anhydrous, Abiraterone Acetate, Gemcitabine Hydrochloride, Cisplatin, Carboplatin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ACHV holds $203.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $9.6M/quarter from operations, an estimated runway of 63.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACHV files for a raise →

👥 Who Owns ACHV

Insiders 7.2% Other 5%+ holders 25.6% Institutions (165 holders) 67.2% Public and other holders 0%
HolderTypeShares% of sharesAs of
venBio Global Strategic Fund V, L.P. 5%+ holder (13D) 10,737,317 9.76% 2026-04-15
Paradigm BioCapital Advisors LP Institution (13G, 5%+) 9,903,712 9.00% 2026-04-17
Franklin Resources, Inc. Institution (13G, 5%+) 8,878,942 8.07% 2026-06-30
Frazier Life Sciences Management, L.P. Institution (13F) 7,614,836 6.92% 2026-09-30
TPG GP A, LLC
10% owner
Insider 6,877,580 6.25% 2026-04-17
Frazier Life Sciences Public Fund, L.P. 5%+ holder (13G) 6,625,788 6.02% 2026-04-17
venBio Partners LLC Institution (13F) 5,914,720 5.38% 2026-09-30
Venrock Healthcare Capital Partners III, 5%+ holder (13G) 5,502,064 5.00% 2026-09-30
JANUS HENDERSON GROUP Ltd. Institution (13G, 5%+) 5,502,064 5.00% 2026-06-30
Venrock Adviser, LLC Institution (13F) 5,502,064 5.00% 2026-09-30
Vivo Opportunity, LLC 5%+ holder (13G) 5,305,640 4.82% 2026-07-06
BlackRock, Inc. Institution (13G, 5%+) 5,271,391 4.79% 2026-06-30

Share count 110,034,457 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-05
filed 2026-10-06
Halladay Benjamin
Option award (A) 200,000 – –
2026-08-19
filed 2026-08-21
Stewart Richard Alistair
Sale (S) 20,626 $8.49 208,249
2026-07-27
filed 2026-07-29
Waldman Reid Alexander
Option award (A) 16,700 – –
2026-07-27
filed 2026-07-29
Farrow Jeffrey S
Option award (A) 25,000 – –
2026-07-27
filed 2026-07-29
Farrow Jeffrey S
Option award (A) 16,700 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-06-20 cytisinicline NDA +9% — —

Browse all historical PDUFA outcomes →

Get the full ACHV picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACHV and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.